This is a phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of telitacicept versus placebo while taking standard of care (SOC) treatment in adult subjects with active proliferative lupus nephritis (LN).
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.